Piper Sandler analyst Danielle Brill maintained an Overweight rating and $135 price target on Acceleron Pharma, as the reblozyl launch is now underway, and label expansion for MDS is expected by its April 4 PDUFA date. Brill said that while management is reportedly pleased with teh growth they are seeing, they are not anticipating meaningful revenue generation until later this year when MDS starts to ramp. The analyst added that a planned meeting with the FDA to discuss the next steps for development will be a "significant" catalyst, and that Acceleron remains a top pick ahead of sotatercept data at ATS.